Stock Traders Purchase High Volume of Call Options on Sanofi (NASDAQ:SNY)

Sanofi (NASDAQ:SNYGet Rating) saw some unusual options trading activity on Friday. Stock traders acquired 3,211 call options on the company. This represents an increase of 93% compared to the typical volume of 1,666 call options.

Institutional Trading of Sanofi

A number of institutional investors and hedge funds have recently bought and sold shares of the business. GHP Investment Advisors Inc. acquired a new stake in shares of Sanofi in the first quarter valued at approximately $26,000. Fairfield Bush & CO. purchased a new stake in shares of Sanofi during the first quarter worth approximately $26,000. Eagle Bay Advisors LLC purchased a new stake in shares of Sanofi during the second quarter worth approximately $28,000. Pinnacle Bancorp Inc. raised its position in Sanofi by 49.0% in the first quarter. Pinnacle Bancorp Inc. now owns 587 shares of the company’s stock worth $30,000 after acquiring an additional 193 shares in the last quarter. Finally, Ahrens Investment Partners LLC purchased a new position in Sanofi in the first quarter worth $31,000. 10.33% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Stock Performance

Shares of NASDAQ:SNY traded down $0.66 during trading on Friday, hitting $38.47. 31,728 shares of the stock traded hands, compared to its average volume of 2,093,357. The company has a quick ratio of 0.34, a current ratio of 1.29 and a debt-to-equity ratio of 0.22. The company has a market cap of $97.52 billion, a price-to-earnings ratio of 12.76, a P/E/G ratio of 0.98 and a beta of 0.53. The company has a fifty day moving average price of $43.81 and a two-hundred day moving average price of $48.70. Sanofi has a 52-week low of $38.66 and a 52-week high of $58.10.

Sanofi (NASDAQ:SNYGet Rating) last announced its earnings results on Thursday, July 28th. The company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.07. The company had revenue of $10.78 billion for the quarter, compared to analysts’ expectations of $10.32 billion. Sanofi had a net margin of 16.60% and a return on equity of 25.99%. As a group, equities analysts predict that Sanofi will post 4.14 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on SNY. TheStreet cut shares of Sanofi from a “b-” rating to a “c+” rating in a research note on Thursday, September 15th. raised shares of Sanofi from a “buy” rating to a “strong-buy” rating in a report on Sunday, August 14th. JPMorgan Chase & Co. raised their price target on shares of Sanofi from €105.00 ($107.14) to €115.00 ($117.35) in a report on Monday, August 1st. Deutsche Bank Aktiengesellschaft cut their price target on shares of Sanofi from €90.00 ($91.84) to €85.00 ($86.73) and set a “hold” rating for the company in a report on Wednesday, September 7th. Finally, Credit Suisse Group raised their price objective on shares of Sanofi from €105.00 ($107.14) to €110.00 ($112.24) and gave the company an “outperform” rating in a research report on Friday, July 22nd. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to, the company currently has a consensus rating of “Moderate Buy” and an average target price of $105.38.

Sanofi Company Profile

(Get Rating)

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.

Featured Stories

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with's FREE daily email newsletter.